AbSci Corp (ABSI): Price and Financial Metrics

AbSci Corp (ABSI): $4.37

0.59 (-11.90%)

POWR Rating

Component Grades








Add ABSI to Watchlist
Sign Up

Industry: Biotech




#290 of 354

in industry

ABSI Price/Volume Stats

Current price $4.37 52-week high $6.72
Prev. close $4.96 52-week low $1.11
Day low $4.34 Volume 2,706,700
Day high $5.20 Avg. volume 1,350,455
50-day MA $4.88 Dividend yield N/A
200-day MA $3.44 Market Cap 494.18M

ABSI Stock Price Chart Interactive Chart >

AbSci Corp (ABSI) Company Bio

Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.

ABSI Latest News Stream

Event/Time News Detail
Loading, please wait...

ABSI Latest Social Stream

Loading social stream, please wait...

View Full ABSI Social Stream

Latest ABSI News From Around the Web

Below are the latest news stories about ABSCI CORP that investors may wish to consider to help them evaluate ABSI as an investment opportunity.

Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Absci management is scheduled to present on Thursday, January 11th at 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company’s investor rela

Yahoo | December 28, 2023

Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline

Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten new Active Programs signed for the year VANCOUVER, Wash., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to dev

Yahoo | December 20, 2023

Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy

Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.

Yahoo | December 5, 2023

Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

Collaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and DevelopmentVANCOUVER, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, today announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca'

Yahoo | December 4, 2023

AstraZeneca, AI biologics firm Absci tie up on cancer drug

Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. It did not say what kind of cancer they plan to target. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.

Yahoo | December 3, 2023

Read More 'ABSI' Stories Here

ABSI Price Returns

1-mo -9.43%
3-mo -10.82%
6-mo 60.07%
1-year 155.56%
3-year N/A
5-year N/A
YTD 4.05%
2023 100.00%
2022 -74.39%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!